

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G/A

Altus Pharmaceuticals Inc.  
Form SC 13G/A  
July 27, 2009

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934\*

(Amendment No. 1)

Altus Pharmaceuticals, Inc.  
-----

(Name of Issuer)

Common Stock, par value \$0.01 per share  
-----

(Title of Class of Securities)

02216N105  
-----

(CUSIP Number)

July 22, 2009  
-----

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to  
which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

-----  
CUSIP No. 02216N105  
-----

13G

-----  
Page 2 of 8 Pages  
-----

-----  
1

NAME OF REPORTING PERSON

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G/A

Warburg Pincus Private Equity VIII, L.P.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\* (a) [ ]  
(b) [X]

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

	5	SOLE VOTING POWER
		0
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	6	SHARED VOTING POWER
		955,624
	7	SOLE DISPOSITIVE POWER
		0
	8	SHARED DISPOSITIVE POWER
		955,624

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
955,624

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES\*  
N/A

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  
3.00%

12 TYPE OF REPORTING PERSON  
PN

CUSIP No. 02216N105

13G

Page 3 of 8 Pages

1 NAME OF REPORTING PERSON

Warburg Pincus & Co.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\* (a) [ ]

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G/A

(b) [X]

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

New York

5 SOLE VOTING POWER

0

NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY  
EACH  
REPORTING  
PERSON  
WITH

6 SHARED VOTING POWER

955,624

7 SOLE DISPOSITIVE POWER

0

8 SHARED DISPOSITIVE POWER

955,624

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

955,624

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES\*

N/A

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

3.00%

12 TYPE OF REPORTING PERSON

PN

CUSIP No. 02216N105

13G

Page 4 of 8 Pages

1 NAME OF REPORTING PERSON

Warburg Pincus LLC

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a) [ ]

(b) [X]

3 SEC USE ONLY

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G/A

4 CITIZENSHIP OR PLACE OF ORGANIZATION  
New York

5 SOLE VOTING POWER  
0

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

6 SHARED VOTING POWER  
955,624

7 SOLE DISPOSITIVE POWER  
0

8 SHARED DISPOSITIVE POWER  
955,624

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
955,624

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES\*  
N/A

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  
3.00%

12 TYPE OF REPORTING PERSON  
OO

CUSIP No. 02216N105 13G Page 5 of 8 Pages

1 NAME OF REPORTING PERSON  
Warburg Pincus Partners LLC

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*  
(a) [ ]  
(b) [X]

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION  
New York

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G/A

	5	SOLE VOTING POWER	
			0
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	6	SHARED VOTING POWER	
			955,624
	7	SOLE DISPOSITIVE POWER	
			0
	8	SHARED DISPOSITIVE POWER	
			955,624
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
			955,624
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*		
			N/A
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9		
			3.00%
12	TYPE OF REPORTING PERSON		
			OO

CUSIP No. 02216N105	13G	Page 6 of 8	Pages
---------------------	-----	-------------	-------

1	NAME OF REPORTING PERSON		
			Charles R. Kaye
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*		
		(a) [ ]	
		(b) [X]	
3	SEC USE ONLY		
4	CITIZENSHIP OR PLACE OF ORGANIZATION		
			United States
	5	SOLE VOTING POWER	
			0

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G/A

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	6	SHARED VOTING POWER	955,624
	7	SOLE DISPOSITIVE POWER	0
	8	SHARED DISPOSITIVE POWER	955,624
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	955,624		
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*		
	N/A		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9		
	3.00%		
12	TYPE OF REPORTING PERSON		
	IN		

CUSIP No. 02216N105 13G Page 7 of 8 Pages

1	NAME OF REPORTING PERSON		
	Joseph P. Landy		
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*		
		(a)	[ ]
		(b)	[X]
3	SEC USE ONLY		
4	CITIZENSHIP OR PLACE OF ORGANIZATION		
	United States		
	5	SOLE VOTING POWER	0
NUMBER OF SHARES BENEFICIALLY	6	SHARED VOTING POWER	955,624

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G/A

OWNED BY	-----	
EACH	7	SOLE DISPOSITIVE POWER
REPORTING		
PERSON	0	
WITH	-----	
	8	SHARED DISPOSITIVE POWER
		955,624
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	955,624	
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	
	N/A	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9	
	3.00%	
12	TYPE OF REPORTING PERSON	
	IN	

This Amendment No. 1 to Schedule 13G (this "Amendment No. 1") is being filed with respect to the common stock, par value \$0.01 per share (the "Common Stock"), of Altus Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the "Company"), to amend the Schedule 13G filed on May 18, 2007 (the "Schedule 13G"). This Amendment No. 1 is being filed on behalf of Warburg Pincus Private Equity VIII, L.P., a Delaware limited partnership, Warburg Pincus & Co., a New York general partnership, Warburg Pincus LLC, a New York limited liability company, Warburg Pincus Partners, LLC, a New York limited liability company, Charles R. Kaye and Joseph P. Landy (collectively, the "Warburg Pincus Reporting Persons") to disclose that the Warburg Pincus Reporting Persons no longer beneficially own more than 5% of the Common Stock. Capitalized terms used herein and not otherwise defined have the meanings ascribed to them in the Schedule 13G.

Item 4: Ownership:  
-----

The information required by Items 4(a) - (c) is set forth in Rows 4-11 of the cover page hereto for each Warburg Pincus Reporting Person and is incorporated herein by reference for each such Warburg Pincus Reporting Person. The ownership percentages set forth in Rows 4-11 of the cover page are calculated based on 31,131,056 shares of Common Stock issued and outstanding as of June 15, 2009, as reported in the Company's Registration Statement on Form S-3 filed with the U.S. Securities and Exchange Commission on June 23, 2009.

Item 5: Ownership of Five Percent or Less of a Class:  
-----

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G/A

Item 10: Certification:  
-----

Each of the Warburg Pincus Reporting Persons hereby makes the following certification:

By signing below, the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

[Signatures on following page]

8

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: July 24, 2009

WARBURG PINCUS PRIVATE EQUITY VIII, L.P.  
By: Warburg Pincus Partners, LLC,  
its General Partner

By: Warburg Pincus & Co.,  
its Managing Member

By: /s/ Scott A. Arenare

-----  
Name: Scott A. Arenare  
Title: Partner

Dated: July 24, 2009

WARBURG PINCUS PARTNERS, LLC  
By: Warburg Pincus & Co.,  
its Managing Member

By: /s/ Scott A. Arenare

-----  
Name: Scott A. Arenare  
Title: Partner

Dated: July 24, 2009

WARBURG PINCUS LLC

By: /s/ Scott A. Arenare

-----  
Name: Scott A. Arenare  
Title: Member



Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G/A

Dated: July 24, 2009

WARBURG PINCUS & CO.

By: /s/ Scott A. Arenare

-----  
Name: Scott A. Arenare  
Title: Partner

Dated: July 24, 2009

By: /s/ Scott A. Arenare

-----  
Name: Charles R. Kaye  
By: Scott A. Arenare, Attorney-in-Fact\*

Dated: July 24, 2009

By: /s/ Scott A. Arenare

-----  
Name: Joseph P. Landy  
By: Scott A. Arenare, Attorney-in-Fact\*\*

\* Power of Attorney given by Mr. Kaye was previously filed with the SEC on March 2, 2006 as an exhibit to a Schedule 13D filed by Building Products, LLC with respect to Builders FirstSource, Inc.

\*\* Power of Attorney given by Mr. Landy was previously filed with the SEC on March 2, 2006 as an exhibit to a Schedule 13D filed by Building Products, LLC with respect to Builders FirstSource, Inc.